Anidulafungin may be an option for patients with esophageal candidiasis
=======================================================================

ST. LOUIS (MD Consult)---Anidulafungin is a new echinocandin that is effective against *Candida* and *Aspergillus* in animal models. A new study suggests that anidulafungin is as effective as fluconazole for patients with esophageal candidiasis.

Dr. David S. Krause and colleagues of Vicuron Pharmaceuticals in King of Prussia, Pa, and other institutions discuss their findings in the September 15 *Clinical Infectious Diseases.*

The authors studied 601 patients with esophageal candidiasis (45% men; mean age, 37 years); 76% of patients had acquired immunodeficiency syndrome. Patients were randomized to receive either intravenous anidulafungin (100 mg on day 1, then 50 mg/day) or oral fluconazole (200 mg on day 1, then 100 mg/day).

Treatments were continued until 7 days after symptoms resolved.

At the end of therapy (range, 14 to 21 days), the rate of endoscopic cure or improvement with anidulafungin (242 out of 249 treated patients \[97.2%\]) was similar to that found with fluconazole (252 out of 255 treated patients \[98.8%\]). Most patients in both groups (88.0% with anidulafungin, 93.3% with fluconazole) had endoscopic cure (i.e., normal mucosa) at the end of treatment.

Drug-related adverse event rates were similar between the anidulafungin and fluconazole groups (9.3% and 12.0%, respectively), as were hematologic and hepatic parameters.

Thus, when taken for 7 days after symptom resolution, anidulafungin is as safe and effective as fluconazole for the treatment of esophageal candidiasis. In fact, anidulafungin may have an advantage, because other data suggest that it is effective even against *Candida* strains that are resistant to fluconazole and amphotericin.

*Clin Infect Dis* 2004;**39**:770--5.

HCV infection is strongly associated with thrombocytopenia
==========================================================

ST. LOUIS (MD Consult)---Patients with hepatitis C virus (HCV) infection are at a greatly increased risk of thrombocytopenia, according to the September 15 *Clinical Infectious Disease.*

Dr. Chong-Shan Wang and colleagues of National Cheng Kung University Hospital in Tainan, Taiwan, and other institutions studied 1,690 subjects ≥40 years old (60% women) living in an area in which HCV is hyperendemic.

All subjects underwent physical examinations and provided serum samples for determining platelet counts, hepatitis B virus (HBV) surface antigen (HBsAg), and antibodies to HCV (anti-HCV).

In all, 70% of subjects were seronegative for both HBV and HCV, 17.4% were positive for anti-HCV, 9.2% were positive for HBsAg, and 3.4% were coinfected with both HBV and HCV. Thrombocytopenia (platelet count \<100,000 cells/μL) was more common in subjects with anti-HCV (10.2%) than in coinfected subjects (5.2%), subjects with HBsAg (1.9%), and seronegative subjects (1.3%).

Multiple logistic regression analyses identified 3 significant and independent predictors of thrombocytopenia: anti-HCV positivity (odds ratio \[OR\], 6.0); age ≥65 years (OR, 4.3); and alanine aminotransferase level ≥40 U/L (OR, 2.1).

Furthermore, in subjects with HBsAg, only patients with advanced liver disease had thrombocytopenia. By contrast, in subjects with anti-HCV, the prevalence of thrombocytopenia increased as the severity of liver disease increased.

Given these strong associations between HCV infection and thrombocytopenia, the authors suggest that patients with thrombocytopenia should be carefully evaluated for possible liver damage and HCV infection.

*Clin Infect Dis* 2004;**39**:790--6.

Combination of voriconazole and caspofungin is more effective for invasive aspergillosis
========================================================================================

ST. LOUIS (MD Consult)---Combining an azole such as voriconazole (which targets the fungal cell membrane) with an echinocandin such as caspofungin (which targets the fungal cell wall) appears effective and safe for patients with refractory invasive aspergillosis, according to a new study.

Dr. Kieren A. Marr and colleagues of the Fred Hutchinson Cancer Research Center in Seattle, Wash, discuss their findings in the September 15 *Clinical Infectious Diseases.*

The authors studied 47 patients with invasive aspergillosis (62% females, 16 to 66 years old) who failed treatment with amphotericin B formulations. Patients were treated with either voriconazole alone (6 mg/kg on day 1, followed by 4 mg/kg twice daily; *n*=31) or voriconazole (same schedule) plus caspofungin (70 mg on day 1, then 50 mg 4 times daily; *n*=16).

Kaplan--Meier analyses showed that the 3-month survival rate after the start of salvage therapy was significantly higher with combination therapy (about 65%) than with voriconazole alone (about 32%) (hazard ratio, 0.42).

Multivariate Cox regression analysis confirmed that combination salvage therapy was a significant and independent predictor of reduced mortality (hazard ratio, 0.28). This was true regardless of conditioning therapy (myeloablative or other) and patient type (stem cell transplant recipient or other).

The probability of death as a result of invasive aspergillosis was also significantly lower with combined therapy (about 52% versus about 20%).

Hepatic and renal function during the first 3 months of salvage therapy did not differ significantly between the 2 groups.

The authors call for randomized trials to determine the efficacy and safety an azole and an echinocandin in combination as primary therapy for invasive aspergillosis.

*Clin Infect Dis* 2004;**39**:797--802.

Micafungin is as effective as fluconazole for HIV-associated esophageal candidiasis
===================================================================================

ST. LOUIS (MD Consult)---Patients with human immunodeficiency virus (HIV) infection are at increased risk of esophageal candidiasis. The new echinocandin agent micafungin appears to be as effective and safe as standard fluconazole in these patients, according to the September 15 *Clinical Infectious Diseases.*

Dr. N. de Wet and colleagues of Prime Cure Clinic in Durban, South Africa, and other institutions studied 245 adults (48% men; mean age, about 35 years) with HIV or acquired immunodeficiency syndrome and esophageal candidiasis.

Patients were randomized into 4 groups to receive intravenous fluconazole (200 mg/day) or 50, 100, or 150 mg/day of intravenous micafungin. Patients were treated for at least 14 days and up to 21 days, if needed, for endoscopic clearance (defined as grade 0 lesions or normal mucosa).

At the end of therapy, endoscopic clearance rates were better with higher doses of micafungin, with clearance rates of 68.8%, 77.4%, and 89.9% at dosages of 50, 100, and 150 mg/day, respectively. The combined rate for the 2 higher dosages (83.5%) did not differ significantly from that found in the fluconazole group (86.7%).

In most patients in all groups, symptoms improved within 3 to 7 days of starting therapy.

Drug-related adverse events were similar in all 4 groups, with no evidence of a dose-response relationship for the higher doses of micafungin.

At the 100 and 150 mg/day dosages, then, micafungin is as effective and safe as standard intravenous fluconazole for treating severely immunocompromised patients with esophageal candidiasis. Micafungin may be particularly valuable, because azole-resistant strains of *Candida* are increasingly being reported in patients with HIV infection.

*Clin Infect Dis* 2004;**39**:842--9.

SARS antibody test for serosurveillance
=======================================

A peptide-based enzyme-linked immunosorbent assay (ELISA) can be used for retrospective serosurveillance of severe acute respiratory syndrome (SARS) by helping identify undetected chains of disease transmission. The assay was developed by epitope mapping, using synthetic peptides from the spike, membrane, and nucleocapsid protein sequences of SARS-associated coronavirus. The new peptide ELISA consistently detected seroconversion by week 2 of onset of fever, and seropositivity remained through day 100. Specificity was 100% on normal blood donor samples, on serum samples associated with infection by other pathogens, and on an interference panel. The peptide-based test has advantages of safety, standardization, and automation over previous immunoassays for SARS. The assay was used for a retrospective survey of healthy healthcare workers in Taiwan who treated SARS patients. Asymptomatic seroconversions were detected in two hospitals that had nosocomial disease.

*Emerg Infect Dis* \[serial on the Internet\] 2004 Sep \[cited 30 August 2004\]. Available from: <http://www.cdc.gov/ncidod/eid/vol10no9/04-0101.htm>.

Foodborne botulism in the United States, 1990--2000
===================================================

Foodborne botulism, a potentially lethal neuroparalytic disease, is caused by ingesting preformed *Clostridium botulinum* neurotoxin. We reviewed surveillance data and reports from 1990 to 2000. Of 263 cases from 160 foodborne botulism events (episode of one or more related cases) in the United States, 103 (39%) cases and 58 events occurred in Alaska. Patients\' median age was 48 years; 154 (59%) were female; the case-fatality rate was 4%. The median number of cases per event was 1 (range 1--17). Toxin type A caused 51% of all cases; toxin type E caused 90% of Alaska cases. A particular food was implicated in 126 (79%) events. In the lower 49 states, a noncommercial food item was implicated in 70 (91%) events, most commonly home-canned vegetables (44%). Two restaurant-associated outbreaks affected 25 persons. All Alaska cases were attributable to traditional Alaska Native foods. Botulism prevention efforts should be focused on those who preserve food at home, Alaska Natives, and restaurant workers.

*Emerg Infect Dis* \[serial on the Internet\] 2004 Sep \[cited 30 August 2004\]. Available from: <http://www.cdc.gov/ncidod/eid/vol10no9/03-0745.htm>.

Computer algorithms to detect bloodstream infections
====================================================

We compared manual and computer-assisted bloodstream infection surveillance for adult inpatients at two hospitals. We identified hospital-acquired, primary, central-venous catheter (CVC)-associated bloodstream infections by using five methods: retrospective, manual record review by investigators; prospective, manual review by infection control professionals; positive blood culture plus manual CVC determination; computer algorithms; and computer algorithms and manual CVC determination. We calculated sensitivity, specificity, predictive values, plus the kappa statistic (*K*) between investigator review and other methods, and we correlated infection rates for seven units. The *K* value was 0.37 for infection control review, 0.48 for positive blood culture plus manual CVC determination, 0.49 for computer algorithm, and 0.73 for computer algorithm plus manual CVC determination. Unit-specific infection rates, per 1000 patient days, were 1.0? 12.5 by investigator review and 1.4? 10.2 by computer algorithm (correlation *r*=0.91, *p*=0.004). Automated bloodstream infection surveillance with electronic data is an accurate alternative to surveillance with manually collected data.

*Emerg Infect Dis* \[serial on the Internet\] 2004 Sep \[cited 30 August 2004\]. Available from: <http://www.cdc.gov/ncidod/eid/vol10no9/03-0978.htm>.

Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia
========================================================================================================================

The Binax NOW immunochromatographic test (ICT) detecting the pneumococcal C polysaccharide and a serotype-specific latex agglutination (LA) test detecting 23 pneumococcal capsular antigens were evaluated for establishing pneumococcal etiology in community-acquired pneumonia (CAP) by use of nonconcentrated urine. ICT was considered to be strongly positive for result lines at least as intense as the control line and weakly positive for less intense result lines. When 215 adult CAP patients were tested, strong ICT, weak ICT, and LA positivity were found in 28, 24, and 16 patients, respectively; of these patients, 13 (46%), 6 (25%), and 13 (81%), respectively, had pneumococcal bacteremia and 27 (96%), 17 (71%), and 15 (94%), respectively, had *Streptococcus pneumoniae* isolated from blood, sputum, and/or nasopharynx. Among 108 controls tested, 2 (1.9%) were weakly ICT positive. When weak positivity was considered negative, the sensitivity of ICT decreased from 79% (19 of 24) to 54% (13 of 24), while the specificity increased from 83% (158 of 191) to 92% (176 of 191); no controls were false positive. The sensitivity and specificity of LA were 54% (13 of 24) and 98% (188 of 191), respectively. Eight of nine LA serotypes corresponded to culture serotypes. In conclusion, using nonconcentrated urine and dividing ICT-positive results into strongly and weakly positive results is a suitable way of performing ICT. While weak ICT positivity should be interpreted with caution, strong ICT positivity and LA positivity should be considered supportive of pneumococcal etiology in adult CAP. As such, these assays might have implications for antibiotic use in CAP. LA has promising potential for pneumococcal serotyping, although further evaluation is required.

*J Clin Microbiol* 2004;**42**(8):3620--5.

PMID: 15297507 \[PubMed---in process\]

Analysis of clonal composition of *Mycobacterium tuberculosis* isolates in primary infections in children
=========================================================================================================

The assumption that *Mycobacterium tuberculosis* infections should be considered clonally homogeneous has been weakened in the last few years. Recent studies have shown (i) the isolation of different *M. tuberculosis* strains from sequential episodes, (ii) mixed infections by two *M. tuberculosis* strains, and (iii) genetic variations in *M. tuberculosis* subpopulations due to microevolution events. Nevertheless, it is unknown whether clonal heterogeneity could be found in the initial steps of *M. tuberculosis* infection, i.e., the primary infection. In the present study we analyzed the clonal composition of the *M. tuberculosis* isolates causing primary infections in children. Cultures were clonally homogeneous in most cases (11 of 12). In 1 of the 12 cases (8.3%), clonal heterogeneity among the *M. tuberculosis* isolates was found by spoligotyping and IS6110-based restriction fragment length polymorphism analysis. This case occurred in a 2-year-old child in whom microevolution events were unlikely and who had no risk factors for overexposure to *M. tuberculosis*. Clonal heterogeneity should also be considered in primary *M. tuberculosis* infections, including circumstances in which it is usually unexpected.

*J Clin Microbiol* 2004;**42**(8):3415--8.

PMID: 15297476 \[PubMed---in process\]

Rapid differentiation of *Aspergillus* species from other medically important opportunistic molds and yeasts by PCR-enzyme immunoassay
======================================================================================================================================

We developed a PCR-based assay to differentiate medically important species of *Aspergillus* from one another and from other opportunistic molds and yeasts by employing universal, fungus-specific primers and DNA probes in an enzyme immunoassay format (PCR-EIA). Oligonucleotide probes, directed to the internal transcribed spacer 2 region of ribosomal DNA from *Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, Aspergillus terreus, Aspergillus ustus*, and *Aspergillus versicolor*, differentiated 41 isolates (3 to 9 each of the respective species; *P*\<0.001) in a PCR-EIA detection matrix and gave no false-positive reactions with 33 species of Acremonium, Exophiala, Candida, Fusarium, Mucor, Paecilomyces, Penicillium, Rhizopus, Scedosporium, Sporothrix, or other aspergilli tested. A single DNA probe to detect all seven of the most medically important Aspergillus species (*A. flavus, A. fumigatus, A. nidulans, A. niger, A. terreus, A. ustus*, and *A. versicolor*) was also designed. Identification of *Aspergillus* species was accomplished within a single day by the PCR-EIA, and as little as 0.5 pg of fungal DNA could be detected by this system. In addition, fungal DNA extracted from tissues of experimentally infected rabbits was successfully amplified and identified using the PCR-EIA system. This method is simple, rapid, and sensitive for the identification of medically important *Aspergillus* species and for their differentiation from other opportunistic fungi.

*J Clin Microbiol* 2004;**42**(8):3495--504.

PMID: 15297489 \[PubMed---in process\]

Evaluation of the QuickLab RSV test, a new rapid lateral-flow immunoassay for detection of respiratory syncytial virus antigen
==============================================================================================================================

Rapid respiratory syncytial virus (RSV) diagnosis is vital to the prevention of nosocomial RSV infections. We evaluated a new rapid lateral-flow RSV immunoassay, the QuickLab RSV test that requires use of only one reagent. We compared QuickLab to the Directigen RSV (DIR) assay, which requires six reagents, and direct fluorescent antibody (DFA) testing. DFA results were considered the "gold standard." For 133 nasopharyngeal aspirates tested, DFA results were 77 (57.8%) positive, 47 (35.3%) negative, and 9 (6.8%) indeterminate. The sensitivities, specificities, positive predictive values, and negative predictive values of QuickLab and DIR tests were 93.3% (70 of 75) and 80.8% (59 of 73), 95.6% (43 of 45) and 100.0% (46 of 46), 97.2% (70 of 72) and 100.0% (59 of 59), and 89.6% (43 of 48) and 76.7% (46 of 60), respectively. QuickLab was significantly (*P*=0.02) more sensitive than DIR; the difference in specificities was not significant. DFA was more sensitive than DIR (*P*\<0.001) but not more sensitive than QuickLab (*P*=0.45). The results of DIR testing were initially uninterpretable and required retesting with 15% of the specimens compared to 3% of QL results (*P*\<0.001). We conclude that the QuickLab RSV test has sensitivity similar to that of the DFA assay and better than that of the DIR assay. QuickLab testing is also simpler to perform and interpret than both DFA and DIR testing.

*J Clin Microbiol* 2004;**42**(8):3731--3.

PMID: 15297522 \[PubMed---in process\]

Mortality in HIV-seropositive versus-seronegative persons in the era of highly active antiretroviral therapy; implications for when to initiate therapySeptember 7, 2004
========================================================================================================================================================================

**Background**: The optimal time to initiate highly active antiretroviral therapy (HAART) remains unclear.

**Methods**: Five hundred eighty-three human immunodeficiency virus (HIV)-seropositive and 920 HIV-seronegative injection drug users (IDUs) were followed from 1997 to 2000. HIV-seropositive participants were categorized according to receipt of HAART (either initiated or switched to HAART) and initial CD4 cell count. Survival analysis that included delayed-entry and Cox proportional-hazards models was used to evaluate the effect of HAART, with adjustments for factors associated with access to HAART.

**Results**: Compared with HIV-seronegative participants, overall survival was similar in HIV-seropositive participants who received HAART at \>350 CD4 cells/μL, but mortality was higher both in participants with \>350 CD4 cells/μL who did not receive HAART and in participants who received HAART at 200--350 CD4 cells/μL (mortality rates, 19.9, 24.0, 43.0, and 50.5/1000 person-years, respectively). In proportional-hazards models in which HIV-seronegative participants were the reference group and in which age, sex, race, frequency of drug use, substance-abuse treatment, and health-care utilization were adjusted for, hazard ratios were 1.01 (95% confidence interval \[CI\], 0.41--2.45), 2.28 (95% CI, 1.38--3.78), and 2.09 (95% CI, 1.07--4.10) for the latter 3 groups. In HIV-seropositive participants, HAART significantly improved survival when initiated at CD4 cell counts \<200 cells/μL.

**Conclusions**: Survival of HIV-seropositive participants receiving HAART approximated that of HIV-seronegative participants only when therapy was given at CD4 cell counts \>350 cells/μL. These data, restricted to IDUs, suggest initiating or switching to HAART at higher CD4 cell levels than are currently recommended.

*J Infect Dis* 2004;**190**(6):1046--54.
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Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling
======================================================================================================================================================

The seroincidence of herpes simplex virus type 2 (HSV-2) infection was determined among 1766 patients attending sexually transmitted disease (STD) clinics and enrolled in a randomized, controlled trial of human immunodeficiency virus (HIV)/STD risk-reduction counseling (RRC). Arm 1 received enhanced RRC (4 sessions); arm 2, brief RRC (2 sessions); and arm 3, the control arm, brief informational messages. The overall incidence rate was 11.7 cases/100 person-years (py). Independent predictors of incidence of HSV-2 infection included female sex; black race; residence in Newark, New Jersey; \<50% condom use with an occasional partner; and, in females, incident trichomoniasis and bacterial vaginosis. Only 10.8% of new HSV-2 infections were diagnosed clinically. Incidence rates were 12.9 cases/100 py in the control arm, 11.8 cases/100 py in arm 2, and 10.3 cases/100 py in arm 1 (hazard ratio, 0.8 \[95% confidence interval, 0.6--1.1\], vs. controls). The possible benefit of RRC in preventing acquisition of HSV-2 infection offers encouragement that interventions more specifically tailored to genital herpes may be useful and should be an important focus of future studies.

*J Infect Dis* 2004;**190**(6):1059--67.

PMID: 15319854 \[PubMed---in process\]

Direct sequencing of SARS-coronavirus S and N genes from clinical specimens shows limited variation
===================================================================================================

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged, in November 2002, as a novel agent causing severe respiratory illness. To study sequence variation in the SARS-CoV genome, we determined the nucleic acid sequence of the S and N genes directly from clinical specimens from 10 patients---1 specimen with no matched SARS-CoV isolate, from 2 patients; multiple specimens from 3 patients; and matched clinical-specimen/cell-culture-isolate pairs from 6 patients. We identified 3 nucleotide substitutions that were most likely due to natural variation and 2 substitutions that arose after cell-culture passage of the virus. These data demonstrate the overall stability of the S and N genes of SARS-CoV over 3 months during which a minimum of 4 generations for transmission events occurred. These findings are a part of the expanding investigation of the evolution of how this virus adapts to a new host.

*J Infect Dis* 2004;**190**(6):1127--31.
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Prolonged diarrhea due to ciprofloxacin-resistant *Campylobacter* infection
===========================================================================

**Background**: *Campylobacter* causes \>1 million infections annually in the United States. Fluoroquinolones (e.g., ciprofloxacin) are used to treat *Campylobacter* infections in adults. Although human infections with ciprofloxacin-resistant *Campylobacter* have become increasingly common, the human health consequences of such infections are not well described.

**Methods**: A case-control study of persons with sporadic *Campylobacter* infection was conducted within 7 FoodNet sites during 1998--1999. The E-test system (AB Biodisk) was used to test for antimicrobial susceptibility to ciprofloxacin; ciprofloxacin resistance was defined as a ciprofloxacin minimum inhibitory concentration of ≥4 μg/mL. We conducted a case-comparison study of interviewed persons who had an isolate tested.

**Results**: Of 858 isolates tested, 94 (11%) were ciprofloxacin resistant. Among 290 persons with *Campylobacter* infection who did not take antidiarrheal medications, persons with ciprofloxacin-resistant infection had a longer mean duration of diarrhea than did persons with ciprofloxacin-susceptible infection (9 vs. 7 days \[*P*=0.04\]). This difference was even more pronounced among the 63 persons who did not take antidiarrheal medications or antimicrobial agents (12 vs. 6 days \[*P*=0.04\]). In a multivariable analysis-of-variance model, the persons with ciprofloxacin-resistant infection had a longer mean duration of diarrhea than did the persons with ciprofloxacin-susceptible infection (*P*=0.01); this effect was independent of foreign travel. The association between ciprofloxacin resistance and prolonged diarrhea is consistent across a variety of analytical approaches.

**Conclusions**: Persons with ciprofloxacin-resistant *Campylobacter* infection have a longer duration of diarrhea than do persons with ciprofloxacin-susceptible *Campylobacter* infection. Additional efforts are needed to preserve the efficacy of fluoroquinolones.

*J Infect Dis* 2004;**190**(6):1150--7.

PMID: 15319866 \[PubMed---in process\]

Available online 5th November 2004

^☆^Summaries supplied courtesy of MD Consult Infectious Disease www.mdconsult.com
